From the Los Angeles Times: “Pharmaceutical companies raised the “wholesale acquisition cost” of their drugs — the list price for wholesalers without discounts or rebates — by a median of 25.8% from 2017 through the first quarter of 2019, according to the Office of Statewide Health Planning and Development. (The median is the point at which half the prices are higher and half are lower.)
Generic drugs saw the largest median increase, 37.6%, during that time. By comparison, the annual inflation rate during the period was 2%.

 

Read More

From Fox Business: “According to a new report from the Institute for Clinical and Economic Review released on Tuesday, combined price hikes from seven drugs, in 2017 and 2018, contributed to a $5.1 billion increase in U.S. spending. None of those drugs had new important evidence to support the price increase, the study concluded.
AbbVie Inc’s rheumatoid arthritis drug Humira accounted for the biggest increase in drug spending in the U.S. between 2017 and 2018 with a 15.9 percent jump over this period. Ultimately, the drug cost patients and insurers an additional $1.86 billion more than it would have prior to the price jump.
Other top treatments by spending included Roche Holding AG’s cancer drug Rituxan, Pfizer Inc’s pain drug Lyrica, Gilead Sciences Inc’s HIV drug Truvada, Amgen Inc’s white blood cell booster Neulasta, Eli Lilly & Co’s erectile dysfunction drug Cialis and Biogen Inc’s multiple sclerosis treatment Tecfidera.

 

Read More

From the Press Herald: “Maine House Speaker Sara Gideon’s U.S. Senate campaign has been low-key so far, except for its online fundraising efforts.
But Thursday, the Freeport Democrat did some more conventional campaigning in her quest to unseat four-term Republican Sen. Susan Collins.
Gideon spent the morning at The Gendron Franco Center on Cedar Street, then met briefly with protesters in front of Collins’ Lisbon Street office. Later, she met at the Lewiston Public Library with a dozen seniors to talk about prescription drug prices.“

Read More

From CNBC: ““Nancy Pelosi just said that she is interested in lowering prescription drug prices & working on the desperately needed USMCA. She is incapable of working on either,” Trump said in a tweet Wednesday.” Will Nancy Pelosi follow through with her plan for better medication pricing?

Read More

From this article: “Few issues in the 2020 presidential election are as fundamental as health care, a topic that touches every voter. Audience members in WMUR’s “Conversation with the Candidate” series asked the candidates a lot of questions about the topic. From Medicare to drug prices, mental health care to medical research, many of the Democratic candidates had similar philosophies, but there are differences when it comes to strategies for real change.”

Read More

From this article: “A report out this week from the House Ways and Means Committee details the extent to which Americans pay more for drugs than other countries—nearly 4 times as much, in fact.

Although prices vary, Americans pay more, even after accounting for rebates, and the United States could save $49 billion a year just on Medicare Part D by using average drug prices for comparator countries, the report says. In 2016, US spending on combined retail (dispensed at the pharmacy) and non-retail (dispensed in physician offices) drugs totaled $457 billion. Medicare alone spent nearly $130 billion on prescription drugs that year: $99.5 billion for Part D pharmacy drugs and $29.1 billion for Part B physician-administered drugs. Between 2011 and 2016, drug spending nationwide grew by 27%, more than 2.5 times the rate of growth in inflation.”

Read More